Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction

Jeyamalar Rajadurai, Wan Azman Wan Ahmad, Hapizah Nawawi, Choo Gim Hooi, Ng Wai Kiat, Rosli Mohd Ali, Al Fazir Omar, Sazzli Kasim, Oteh Maskon, David Quek Kwang Leng

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease (CVD) has been the main cause of mortality and an important cause of morbidity in Malaysia for several years. To reduce global cardiovascular (CV) risk in the population, primary preventive strategies need to be implemented. Hypercholesterolaemia is one of the major risk factors for CVD. This paper is an expert review on the management of hypercholesterolemia focusing on high and very high risk individuals. In low and Intermediate risk individuals, therapeutic lifestyle changes (TLC) and a healthy lifestyle alone may suffice. In high and very high risk individuals, drug therapy in conjunction with TLC are necessary to achieve the target LDL-C levels which have been shown to slow down progression and sometimes even result in regression of atherosclerotic plaques. Statins are first-line drugs because they have been shown in numerous randomized controlled trials to be effective in reducing CV events and to be safe. In some high risk individuals, despite maximally tolerated statin therapy, target Low Density Lipoprotein Cholesterol (LDL-C) levels are not achieved. These include those with familial hypercholesterolaemia and statin intolerance. This paper discusses non-statin therapies, such as ezetimibe and the newer Proprotein convertase subtilisin/kexin type 9 Inhibitors (PCSK9-i).

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalMedical Journal of Malaysia
Volume73
Issue number3
Publication statusPublished - 1 Jun 2018

Fingerprint

Risk Reduction Behavior
Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
LDL Cholesterol
Life Style
Cardiovascular Diseases
Hyperlipoproteinemia Type II
Malaysia
Atherosclerotic Plaques
Therapeutics
Randomized Controlled Trials
Morbidity
Drug Therapy
Mortality
Pharmaceutical Preparations
Population

Keywords

  • Cardiovascular disease
  • Ezetimibe
  • Familial hypercholesterolaemia
  • Hypercholesterolaemia
  • PCSK9-inhibitor
  • Statin intolerance
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rajadurai, J., Wan Ahmad, W. A., Nawawi, H., Hooi, C. G., Kiat, N. W., Ali, R. M., ... Leng, D. Q. K. (2018). Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction. Medical Journal of Malaysia, 73(3), 154-162.

Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction. / Rajadurai, Jeyamalar; Wan Ahmad, Wan Azman; Nawawi, Hapizah; Hooi, Choo Gim; Kiat, Ng Wai; Ali, Rosli Mohd; Omar, Al Fazir; Kasim, Sazzli; Maskon, Oteh; Leng, David Quek Kwang.

In: Medical Journal of Malaysia, Vol. 73, No. 3, 01.06.2018, p. 154-162.

Research output: Contribution to journalArticle

Rajadurai, J, Wan Ahmad, WA, Nawawi, H, Hooi, CG, Kiat, NW, Ali, RM, Omar, AF, Kasim, S, Maskon, O & Leng, DQK 2018, 'Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction', Medical Journal of Malaysia, vol. 73, no. 3, pp. 154-162.
Rajadurai J, Wan Ahmad WA, Nawawi H, Hooi CG, Kiat NW, Ali RM et al. Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction. Medical Journal of Malaysia. 2018 Jun 1;73(3):154-162.
Rajadurai, Jeyamalar ; Wan Ahmad, Wan Azman ; Nawawi, Hapizah ; Hooi, Choo Gim ; Kiat, Ng Wai ; Ali, Rosli Mohd ; Omar, Al Fazir ; Kasim, Sazzli ; Maskon, Oteh ; Leng, David Quek Kwang. / Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction. In: Medical Journal of Malaysia. 2018 ; Vol. 73, No. 3. pp. 154-162.
@article{f47abe5507e3417798a3358cf2eed14e,
title = "Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction",
abstract = "Cardiovascular disease (CVD) has been the main cause of mortality and an important cause of morbidity in Malaysia for several years. To reduce global cardiovascular (CV) risk in the population, primary preventive strategies need to be implemented. Hypercholesterolaemia is one of the major risk factors for CVD. This paper is an expert review on the management of hypercholesterolemia focusing on high and very high risk individuals. In low and Intermediate risk individuals, therapeutic lifestyle changes (TLC) and a healthy lifestyle alone may suffice. In high and very high risk individuals, drug therapy in conjunction with TLC are necessary to achieve the target LDL-C levels which have been shown to slow down progression and sometimes even result in regression of atherosclerotic plaques. Statins are first-line drugs because they have been shown in numerous randomized controlled trials to be effective in reducing CV events and to be safe. In some high risk individuals, despite maximally tolerated statin therapy, target Low Density Lipoprotein Cholesterol (LDL-C) levels are not achieved. These include those with familial hypercholesterolaemia and statin intolerance. This paper discusses non-statin therapies, such as ezetimibe and the newer Proprotein convertase subtilisin/kexin type 9 Inhibitors (PCSK9-i).",
keywords = "Cardiovascular disease, Ezetimibe, Familial hypercholesterolaemia, Hypercholesterolaemia, PCSK9-inhibitor, Statin intolerance, Statins",
author = "Jeyamalar Rajadurai and {Wan Ahmad}, {Wan Azman} and Hapizah Nawawi and Hooi, {Choo Gim} and Kiat, {Ng Wai} and Ali, {Rosli Mohd} and Omar, {Al Fazir} and Sazzli Kasim and Oteh Maskon and Leng, {David Quek Kwang}",
year = "2018",
month = "6",
day = "1",
language = "English",
volume = "73",
pages = "154--162",
journal = "Medical Journal of Malaysia",
issn = "0300-5283",
publisher = "Malaysian Medical Association",
number = "3",

}

TY - JOUR

T1 - Updates in the management of dyslipidaemia in the high and very high risk individual for CV risk reduction

AU - Rajadurai, Jeyamalar

AU - Wan Ahmad, Wan Azman

AU - Nawawi, Hapizah

AU - Hooi, Choo Gim

AU - Kiat, Ng Wai

AU - Ali, Rosli Mohd

AU - Omar, Al Fazir

AU - Kasim, Sazzli

AU - Maskon, Oteh

AU - Leng, David Quek Kwang

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Cardiovascular disease (CVD) has been the main cause of mortality and an important cause of morbidity in Malaysia for several years. To reduce global cardiovascular (CV) risk in the population, primary preventive strategies need to be implemented. Hypercholesterolaemia is one of the major risk factors for CVD. This paper is an expert review on the management of hypercholesterolemia focusing on high and very high risk individuals. In low and Intermediate risk individuals, therapeutic lifestyle changes (TLC) and a healthy lifestyle alone may suffice. In high and very high risk individuals, drug therapy in conjunction with TLC are necessary to achieve the target LDL-C levels which have been shown to slow down progression and sometimes even result in regression of atherosclerotic plaques. Statins are first-line drugs because they have been shown in numerous randomized controlled trials to be effective in reducing CV events and to be safe. In some high risk individuals, despite maximally tolerated statin therapy, target Low Density Lipoprotein Cholesterol (LDL-C) levels are not achieved. These include those with familial hypercholesterolaemia and statin intolerance. This paper discusses non-statin therapies, such as ezetimibe and the newer Proprotein convertase subtilisin/kexin type 9 Inhibitors (PCSK9-i).

AB - Cardiovascular disease (CVD) has been the main cause of mortality and an important cause of morbidity in Malaysia for several years. To reduce global cardiovascular (CV) risk in the population, primary preventive strategies need to be implemented. Hypercholesterolaemia is one of the major risk factors for CVD. This paper is an expert review on the management of hypercholesterolemia focusing on high and very high risk individuals. In low and Intermediate risk individuals, therapeutic lifestyle changes (TLC) and a healthy lifestyle alone may suffice. In high and very high risk individuals, drug therapy in conjunction with TLC are necessary to achieve the target LDL-C levels which have been shown to slow down progression and sometimes even result in regression of atherosclerotic plaques. Statins are first-line drugs because they have been shown in numerous randomized controlled trials to be effective in reducing CV events and to be safe. In some high risk individuals, despite maximally tolerated statin therapy, target Low Density Lipoprotein Cholesterol (LDL-C) levels are not achieved. These include those with familial hypercholesterolaemia and statin intolerance. This paper discusses non-statin therapies, such as ezetimibe and the newer Proprotein convertase subtilisin/kexin type 9 Inhibitors (PCSK9-i).

KW - Cardiovascular disease

KW - Ezetimibe

KW - Familial hypercholesterolaemia

KW - Hypercholesterolaemia

KW - PCSK9-inhibitor

KW - Statin intolerance

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85049363568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049363568&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 154

EP - 162

JO - Medical Journal of Malaysia

JF - Medical Journal of Malaysia

SN - 0300-5283

IS - 3

ER -